Autoimmune Disease

Biosimilars

We provide patients with
high-quality yet affordable biopharmaceutical treatments

Autoimmune Disease

From first mover to game changer: Celltrion achieved a breakthrough by releasing Remsima, the world’s first antibody biosimilar, to the global market. Remsima provides a broader selection of treatment options to more patients than ever before for an affordable price. As the world’s first biosimilar product trusted by pharmaceutical regulators and patients across the world, Remsima’s effectiveness and safety have been proven by the cumulative number of prescriptions and the results of long-term clinical trials.

Remsima, the world’s first antibody biosimilar

With Remsima, Celltrion occupied 60% of the European autoimmune disease market by becoming the “first mover” in the blockbuster biopharmaceutical market after the expiration of key patents. Remsima has established itself as the leading antibody biosimilar for the treatment of autoimmune diseases.

Remsima SC, New therapeutic option

Based on prescription data and successful clinical results in the past years, Celltrion developed Resima SC, a subcutaneous application of Remsima. Remsima SC, Which recently received EMA approval, is expected to increase access to convenient injections and widen doctor’s treatment options-therefore overcoming limitations of existing TNF-∝ inhibitors and ultimately changing the market paradigm.

Learn more

Pipelines: Celltrion has secured a total of nine pipelines for biosimilar products for autoimmune diseases. In particular, we developed Humira biosimilar CT-P17 in a high concentration formulation for the global market worth approximately KRW 25 trillion. The high concentration gives CT-P17 a competitive edge from our competitors.

Learn more